Every year, hundreds of companies sign Cooperative Research and Development Agreements with DOE national laboratories. Many walk away with little more than a press release.
The agreement itself is not the problem. CRADAs have been a legitimate technology transfer tool since 1989. They give private companies direct access to research infrastructure across DOE’s 17 national labs that would cost hundreds of millions of dollars to replicate independently.
The real problem is preparation. Most companies focus on getting the agreement signed and treat the signature as the finish line instead of the starting point. What follows is often a slow, frustrating collaboration that stalls somewhere in year two.
Three things consistently separate the partnerships that deliver value from the ones that don’t. All three need to happen before a CRADA is ever signed.
A CRADA lets a national lab and a private partner conduct joint research toward goals that serve both the lab’s mission and the company’s development needs. It comes in two forms:
The important distinction
What a CRADA is not is a contract for guaranteed output. There are no built-in deliverables, no timeline enforcement, and no financial penalty if the work moves slowly. Most companies don’t fully appreciate that until they are already inside one.
The single most important factor in whether a partnership delivers results is not the strength of your technology or the quality of your proposal. It is whether you have a genuine internal champion inside the lab, someone with a technical stake in the outcome rather than an administrative sponsor just managing paperwork.
Administrative sponsors keep a CRADA alive on paper. Technical champions keep it alive in practice.
A scientist who is personally invested in your technology will:
National labs are cautious institutions by design. They are evaluated on mission delivery rather than commercial outcomes for their partners, so a lab scientist won’t typically champion your technology unless something in the work genuinely interests them.
This means the champion relationship has to be built before the CRADA, not assumed to appear after signing. Companies should put real time into conference attendance and informal technical conversations, not to pitch the agreement but to find the person who will care about the work when no one is watching. DOE’s Office of Technology Commercialization is a useful starting point for identifying the right labs and program areas, but the relationship itself has to be earned in person.
One of the most consequential decisions a company makes when structuring a CRADA is whether to fund it. Many make that call without understanding what it means in practice.
An unfunded CRADA sounds appealing because it lowers upfront cost and risk. In practice, it also removes nearly all the institutional pressure that would otherwise keep the collaboration moving:
That doesn’t mean unfunded CRADAs have no value. A signed agreement is still a credibility milestone that supports investor confidence and shows the company is engaging seriously with a federal partner. But companies should go in understanding what it is: a relationship-building tool rather than a guaranteed engine of output.
The bottom line
If your company genuinely needs the lab to produce something on a timeline, a funded CRADA is worth the investment. A DOE Inspector General audit of CRADA performance found that resource allocation and accountability directly affect how productively labs engage with private partners, a finding that still holds true today.
The third thing companies consistently fail to do before signing a CRADA is prepare their own leadership for what the next two years will actually look like.
DOE lab partnerships are long-horizon relationships that do not run on commercial timelines. The slow middle stretch, after the agreement is signed and before meaningful output emerges, is where most collaborations either find their footing or quietly lose institutional support.
Sustained engagement
Companies that describe this accurately to their board from the start tend to stay engaged through that stretch
Misaligned expectations
Companies that sell it internally as a near-term R&D accelerator tend to lose patience exactly when the relationship needs sustained attention most
This isn’t unique to CRADAs. DOE’s own SBIR and STTR programs reward companies that can sustain a long development arc, not ones that treat a signed agreement as a finish line. Set the expectation internally before you sign. It is much harder to reset it afterward.
A CRADA with a DOE national laboratory can be a genuinely valuable asset. It can compress years of independent R&D, add credibility with investors, and open doors inside the federal system that are hard to reach any other way. But none of that value is automatic. It is earned through preparation, relationship-building and honest internal alignment on what the partnership actually requires.
The companies that get the most out of DOE relationships are rarely the ones with the strongest technology alone. They are the ones that arrive prepared, with a champion already identified, a clear-eyed funding structure and a leadership team that understands what they signed up for.
Shepherd Strategies works with companies at exactly this stage, before the first conversation with a lab or program office and through the slow middle of a partnership that needs to find its footing. Organizations exploring a DOE engagement can start that conversation with professionals.
© 2026 Shepherd Strategies LLC.
All Rights Reserved.
